CD274 and neoplasm: Although microsatellite instability (MSI), tumor mutational burden (TMB), and PD-1/PD-L1 have been recognized as biomarkers predictive of immunotherapy response, their predictive effects are influenced by tumor heterogeneity and individual differences (6–8).